Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses  by Ho, Ping-Chih et al.
Article
Phosphoenolpyruvate Is a Metabolic Checkpoint of
Anti-tumor T Cell ResponsesGraphical AbstractHighlightsd Glucose deprivation suppresses anti-tumor T cell effector
functions
d Glycolytic metabolite PEP sustains Ca2+ and NFAT signaling
by blocking SERCA
d Ca2+ signaling is an integrator of glycolytic activity and TCR
signaling
d T cell metabolic reprogramming enhances anti-tumor
effector functionsHo et al., 2015, Cell 162, 1217–1228
September 10, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cell.2015.08.012Authors
Ping-Chih Ho, Jessica Dauz Bihuniak,
Andrew N. Macintyre, ..., Marcus W.
Bosenberg, Jeffrey C. Rathmell, SusanM.
Kaech
Correspondence
ping-chih.ho@unil.ch (P.-C.H.),
susan.kaech@yale.edu (S.M.K.)
In Brief
High rates of tumor cell glycolysis
suppress intratumoral T cell function by
depriving T cells of glucose and the
downstream metabolite
phosphoenolpyruvate (PEP), which is
necessary for maximal Ca2+ -NFAT
signaling in T cells. Metabolic rewiring of
T cells to generate PEP in glucose-poor
conditions improves their anti-tumor
responses.
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Activated T cells engage aerobic glycolysis and
anabolic metabolism for growth, proliferation, and
effector functions. We propose that a glucose-poor
tumor microenvironment limits aerobic glycolysis in
tumor-infiltrating T cells, which suppresses tumorici-
dal effector functions. We discovered a new role
for the glycolytic metabolite phosphoenolpyruvate
(PEP) in sustaining T cell receptor-mediated Ca2+-
NFAT signaling and effector functions by repressing
sarco/ERCa2+-ATPase (SERCA) activity. Tumor-spe-
cific CD4 and CD8 T cells could be metabolically re-
programmed by increasing PEP production through
overexpression of phosphoenolpyruvate carboxyki-
nase 1 (PCK1), which bolstered effector functions.
Moreover, PCK1-overexpressing T cells restricted
tumor growth and prolonged the survival of mela-
noma-bearing mice. This study uncovers new meta-
bolic checkpoints for T cell activity and demonstrates
that metabolic reprogramming of tumor-reactive
T cells can enhance anti-tumor T cell responses, illu-
minating new forms of immunotherapy.
INTRODUCTION
Host immunity provides wide spectrum protection that serves to
eradicate cancerous cells in addition to infectious pathogens.
Multiple types of immune cells are involved in tumor immunosur-
veillance and of particular importance are the tumor-infiltrating
lymphocytes (TILs) (i.e., T cells) (Braumu¨ller et al., 2013; Shiao
et al., 2011). In most established tumors, however, the tumorici-
dal effector functions of TILs such as IFNg production and cyto-Ctoxicity are restricted by multiple environmental factors. This
includes the accumulation of immunoregulatory cells such as
regulatory CD4+ T cells (Tregs), myeloid derived suppressor
cells (MDSCs) and tolerogenic antigen-presenting cells (APCs)
(Mellman et al., 2011; Shiao et al., 2011). Additionally, alter-
ations in the availability of nutrients (e.g., lactate and trypto-
phan-related metabolites such as kynurenine) in the tumor
microenvironment can limit TIL activity (Yang et al., 2013).
Another prominent feature of TILs is the increased expression
of inhibitory checkpoint receptors (e.g., programmed cell death
protein 1 [PD-1], lymphocyte-activation gene 3 [Lag3], and
cytotoxic T-lymphocyte-associated protein 4 [CTLA-4]) that
desensitizes T cell receptor (TCR) signaling and contributes
to their functional impairment (Baitsch et al., 2012). T cells dis-
playing such properties are commonly referred to as ‘‘function-
ally exhausted’’ (Wherry, 2011). These discoveries have led
to the development of cancer immunotherapies that reawaken
exhausted TILs by blocking inhibitory checkpoint receptors
such as PD-1 or CTLA-4 or targeting other immunoregulatory
cells. Adoptive cell therapy (ACT) of tumor-specific T cells is
another promising form of anti-cancer immunotherapy that
increases the repertoire of cytotoxic T cells to eradicate estab-
lished tumors. ACT has the added benefit of permitting genetic
modifications of TILs to express proteins that could aide in
tumor destruction (Maude et al., 2014). These breakthroughs
demonstrate that tumor immunotherapy holds great promise
(Callahan et al., 2010; Wolchok et al., 2013), but also present
us with challenges to devise additional treatment options in
conjunction with those currently available to further increase
patient objective responses. To meet these challenges, we
must gain a clearer understanding of what causes T cell
exhaustion in tumors, and we hypothesize that the metabolic
states of the TILs and tumor cells, as well as other cell types
in the tumor microenvironment, are principal components of
this process.ell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc. 1217
Deregulated anabolic metabolism and increased rates of aer-
obic glycolysis (i.e., the Warburg effect), glutaminolysis and fatty
acid synthesis are cardinal features of most tumor cells that fuels
their growth and proliferation (Hanahan and Weinberg, 2011;
Ward and Thompson, 2012). Interestingly, activated T lympho-
cytes undergo a metabolic switch similar to cancer cells and
upregulate aerobic glycolysis and glutaminolysis to permit prolif-
eration and differentiation into specialized effector T cells. Given
their similarities in metabolic profiles and nutrient requirements,
it is possible that the abnormally high metabolic rates and con-
sumption of nutrients by tumor cells competes with neighboring
T cells, which leads to T cell metabolic exhaustion that underlies
their functional exhaustion. Supporting this notion, reports have
shown that the concentration of extracellular glucose are lower in
tumors compared to healthy tissues (Gullino et al., 1964). Thus,
limited glucose availability could be an environmental restriction
that promotes T cell exhaustion, and if true, it is important to
learn how this affects T cell receptor (TCR) signaling and effector
functions in tumors. Perhaps, new therapies directed at reprog-
ramming T cell metabolism could be developed to enhance their
functional fitness in the tumor microenvironment.
TCR stimulation activates numerous key signaling pathways
that coordinately induce anabolic metabolism, aerobic glycol-
ysis, and effector T cell proliferation and differentiation (Smith-
Garvin et al., 2009). Increased aerobic glycolysis is essential
for the production of biosynthetic precursors that fuel effector
T cell proliferation and production of effector molecules like
IFNg, IL-2, and IL-17 and Granzyme B in T cells (Cham et al.,
2008; Chang et al., 2013; Finlay et al., 2012; Michalek et al.,
2011). Activation of PI3K, Akt, and mTOR triggers the switch to
anabolic metabolism by inducing transcription factors such as
Myc and hypoxia-inducible factor 1 (HIF1) (MacIver et al.,
2013; Wang et al., 2011a). T cells rendered functionally anergic
that are unable to activate Ca2+ and nuclear factor of activated
T cells (NFAT) signaling show diminished rates of aerobic glycol-
ysis and anabolic metabolism following stimulation (Srinivasan
and Frauwirth, 2007; Zheng et al., 2009). Similarly, CD8 T cells
with increased PD-1 expression fail to fully activatemTORor aer-
obic glycolysis following TCR stimulation and conversely, those
with hyper-HIF1a activity and aerobic glycolysis are refractory to
functional exhaustion (Doedens et al., 2013; Parry et al., 2005;
Staron et al., 2014). The glycolytic enzymesmay also serve direct
roles in regulating effector functions in T cells because recent
work showed that when glycolytic rates are low, the glyceralde-
hyde phosphate dehydrogenase (GAPDH) binds to and sup-
presses Ifng mRNA translation in T cells (Chang et al., 2013;
Gubser et al., 2013). These findings demonstrate strong inter-
connections between T cell metabolism and effector functions
but little remains known about how metabolic pathways or their
metabolites fine-tune T cell activity.
In this study, we found that intratumoral CD4 T cells displayed
signs of glucose deprivation and diminished anti-tumor effector
functions, suggesting that a glucose-poor tumor microenviron-
ment might contribute to TIL exhaustion. Furthermore, increased
expression of hexokinase 2 (HK2) in tumor cells allowed for more
efficient evasion of CD4 T cell-mediated immune surveillance
indicating that a metabolic competition could exist between
TILs and tumor cells. Linking glucose-deprivation to T cell func-1218 Cell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc.tion, we also discovered that insufficiency of the glycolytic
metabolite phosphoenolpyruvate (PEP) led to defects in
Ca2+-NFAT signaling and T cell activation by increasing
SERCA-mediated Ca2+ re-uptake. Most importantly, we pro-
vided proof-of-concept evidence that metabolic reprogramming
of T cells to increase PEP production could be a promising strat-
egy to elevate T cell mediated anti-tumor immune responses and
improve the effects of adoptive T cell transfer immunotherapy.
RESULTS
Glucose Limitation Suppresses Anti-tumor Effector
Functions of Intratumoral TH1 CD4 T Cells while
Stimulating TGFb Production
To investigate whether limited glucose availability within the tu-
mor microenvironment suppressed aerobic glycolysis and
hence, effector functions in TILs, we first compared the concen-
tration of glucose in the interstitial fluid of the spleen, blood, and
tumors from melanoma-bearing Tyr-creERT2/BrafV600E/Pten-
lox (Braf/Pten) mice (Dankort et al., 2009) (Figure 1A) and B16
melanoma-bearing mice (data not shown). As reported in other
solid tumors (Gullino et al., 1964), the glucose level of the tumor
interstitial fluid (0.6 mM) was approximately ten times lower
than that of the spleen and blood (9 mM). Additionally, intratu-
moral CD44hi CD25lo CD4+ T cells (i.e., activated non-Treg
CD4+ T cells) failed to take-up glucose as efficiently as their
counterparts in the spleen based on intracellular staining with
the fluorescent glucose analog 2-NBDG (Figure 1B). We further
assessed 2NDBG-uptake in tumor infiltrating non-Treg CD4+
T cells, Tregs, tumor-associated macrophages (TAMs), and
MDSCs. This showed that non-Treg CD4+ T cells take-up
marginally less 2NDBG than TAMs, but not MDCSs. Unexpect-
edly, the intramoral and splenic Tregs demonstrated higher
2NDBG uptake compared to the other cell populations
(Figure S1A). Furthermore, co-culturing TH1 CD4+ T cells with
Braf/Pten melanoma cells demonstrated that the presence of
tumor cells could reduce glucose uptake by TH1 cells (Fig-
ure 1C), suggesting that tumor cells may directly restrict glucose
availability for TILs. As there is no facile way to directly and
specifically measure rates of glycolysis in TILs in vivo or in situ,
we attempted to determine if intratumoral CD4+ T cells express
genes induced by glucose deprivation. We identified a ‘‘glucose-
deprivation transcriptional signature’’ in CD4+ T cells by
comparing the differentially expressed genes of activated TH1
cells cultured in high (10mM) or low (0.1mM) glucose concentra-
tions using RNA-sequencing and microarrays (Figure S1B), and
observed that intratumoral CD4+ T cells expressed higher levels
of the glucose-deprived signature genes than CD4+ T cells in the
draining lymph nodes (dLNs) (Figure 1D). This result suggested
that some portion of the CD4+ TILs experienced glucose-depri-
vation within the tumor microenvironment in vivo.
Next, we stimulated functional TH1CD4+ T cells (isolated from
lymphocytic choriomeningitis virus (LCMV)-infected animals) in
different concentrations of glucose (ranging from 0.1–10 mM)
to directly interrogate the effects of glucose deprivation on pro-
duction of CD40 ligand (CD40L) and IFNg—two factors critical
for maintaining an immunostimulatory microenvironment in
the Braf/Pten melanomas (Ho et al., 2014). This showed that
Figure 1. Tumor Microenvironment Deprives Glucose to Infiltrating CD4+ T Cells
(A) Bar graphs show the glucose concentration in blood and interstitial fluid of tumors and spleens from Braf/Pten melanoma-bearing mice.
(B and C) Glucose uptake in splenic and intratumoral CD44+/CD25lo and CD44+/CD25hi CD4+ T cells (B) or in TH1 cells cultured with or without Braf/Pten
melanoma cells (C) was determined using fluorescent 2-NBDG and measured by flow cytometry.
(D) The expression of glucose-deprived signature genes in CD4+ T cells isolated frommelanomas and draining lymph nodes (dLNs) was determined by qRT-PCR.
(E and F) TH1 CD4
+ T cells derived from LCMV Armstrong-infected mice were stimulated by anti-CD3/anti-CD28 mAbs in vitro in the indicated glucose con-
centrations for 5 hr. The expression of IFNg, IL-2, and CD40L was analyzed by flow cytometry (E), and production of TGFb was determined by ELISA (F).
(G) The production of CD40L and IFNg in CD4+ T cells isolated from the dLN, spleen, or tumors in Braf/Pten mice was analyzed by flow cytometry.
(H) LAP surface expression was compared between activated FoxP3+ (Treg) and FoxP3
 (non-Treg) CD4
+ T cells within melanomas using flow cytometry.
(I) Validation of LAP staining as a surrogate for TGFb secreting capability was performed by stimulating purified intratumoral LAP+ and LAP CD44+ CD4 T+ cells
with or without anti-CD3/anti-CD28 mAbs for 16 hr and measuring the amount of TGFb in culture supernatants by ELISA.
(J) The frequency of LAP+ FoxP3+ (Treg) and FoxP3
 (non-Treg) CD4
+ T cells within melanomas or dLNs was assessed using flow cytometry.
Data shown are cumulative of two (A and B, D, H, I) (n = 3–6 mice/group/experiment) and three (G and J) independent experiments (n = 3–4 mice/group/
experiment) or representative of three (C, E and F) independent experiments (n = 3–5/group). Data are expressed as mean ± SD and (C) is presented as mean ±
SEM. *p < 0.05 by unpaired Student’s t test.these effector functions were suppressed by limited amounts of
glucose (Figure 1E). Conversely, glucose deprivation augmented
TGFb production in activated CD4+ T cells (Figure 1F), suggest-
ing that glucose deprivation can cause CD4+ T cells to switch
from immuno-supportive to immuno-suppressive states. Impor-
tantly, the CD4+ T cells isolated directly ex vivo frommelanomas
displayed similar functional attributes to the in vitro glucose-
deprived TH1 cells. For example, the percentage of CD44hiCCD25lo (non-Treg) CD4+ T cells that produced IFNg or CD40L
in the tumors was 50% lower than that in the spleen or dLN
(Figure 1G). Additionally, the expression of the TGFb latency
associated peptide (LAP), a surrogate marker for cells compe-
tent to produce TGFb, was examined on the CD4+ T cells (Fig-
ures 1H–IJ), and this showed that a greater proportion of non-
Treg CD4+ T cells expressed elevated LAP compared to the
FoxP3+ Tregs in both the tumors and dLNs (Figure 1J).ell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc. 1219
Figure 2. HK2 Overexpression in Melanoma
Cells Suppresses CD4+ T Cell-Mediated
Anti-tumor Responses
(A and B) Control (Ctrl) or HK2-OE Braf/Pten tu-
mors were engrafted into the right and left flanks of
C57BL/6 mice. Fourteen days later, the CD4+ TILs
were isolated, stimulated in vitro by anti-CD3/anti-
CD28 mAbs for 5 hr and analyzed for CD40L and
IFNg expression by flow cytometry. Left: percent-
age of CD40L+ (A) or IFNg+ (B); right: mean fluo-
rescence intensity (MFI) of the indicated proteins.
(C–E) Ctrl or HK2-OE Braf/Pten tumors were en-
grafted into the right and left flanks of Rag1-KO
mice mouse that were either injected with PBS or
reconstituted with CD4+ T cells and 14 days later
the weight (C and D) and size (E) of tumors was
assessed. (C and D) Graphs show tumor weights of
the contralateral pairs of ctrl and HK2-OE mela-
nomas collected from same mouse expressed as
actual weights (C) or as a ratio (D).
Data shown are cumulative of three (A and B)
independent experiments (n = 3–4 mice/group) or
four (C and D) independent experiments (n = 2–4
mice/group). Data are expressed as mean ± SD
and *p < 0.05 by unpaired Student’s t test.Collectively, these data demonstrate that CD4+ TILs display ge-
netic and functional features associated with glucose-depriva-
tion and suggest that competition between tumor cells and
TILs for glucose in the tumor microenvironment could contribute
to an immunosuppressive environment.
Increased Rates of Aerobic Glycolysis in Melanoma
Cells Suppress CD4+ T Cell-Mediated
Immunosurveillance
Increased rates of aerobic glycolysis and expression of glyco-
lytic enzymes (e.g., hexokinase 2 [Hk2]) are common hallmarks
of cancer cells (Hanahan and Weinberg, 2011), and this may
lead to glucose-deprivation and T cell dysfunction in tumors as
suggested by the data above. To investigate this hypothesis
further, we analyzed the expression of effector T cell genes
(e.g., Ifng and Cd40lg) and markers of glycolysis (e.g., Hk2)
mRNA within the tumors of 384 melanoma patients (data ob-
tained from The Cancer Genome Atlas [TCGA]) (Cerami et al.,
2012; Gao et al., 2013). Interestingly, this showed that the
amount of Cd40lg and Ifng mRNA inversely correlated with
Hk2 mRNA (Figure S2A). To more directly test if the glycolytic
rates of tumor cells affect tumor immunosurveillance by CD4+
T cells, we established stable clones of the Braf/Pten melanoma
cell line (YUMM1.7) that expressed either a control vector or one
overexpressing HK2 (HK2-OE). As expected, HK2-OE tumor
cells had higher rates of aerobic glycolysis than the control cells
based on extracellular acidification rates (ECAR) using the Sea-
horse Extracellular Flux Analyzer (Figure S2B) and HK2-OE tu-
mor cells more efficiently suppressed glucose uptake of TH1
CD4+ T cells in the co-culture assay (Figure S2C). Then we en-
grafted control and HK2-OE melanoma cell lines into the left
and right flanks, respectively, of wild-type C57BL/6 mice. Two
weeks later, the production of CD40L and IFNg by CD4+ TILs re-
stimulated directly ex vivo was assessed and compared to CD4+1220 Cell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc.T cells isolated from the control melanomas, those isolated from
HK2-OE tumors had lower production of CD40L and IFNg (Fig-
ures 2A and 2B and S2D). This result demonstrated that T cell
effector functions could be affected by the rates of tumor cell
aerobic glycolysis. Next, we compared the growth rates of con-
trol and HK2-OE melanoma cell lines engrafted into the left and
right flanks, respectively, of Rag1-KO mice that were either re-
constituted with CD4+ T cells or not. In accord with higher rates
of aerobic glycolysis, the HK2-OE melanomas grew faster
compared to the control tumors in both groups of mice (Fig-
ure 2C). However, the presence of CD4+ T cells potently sup-
pressed the growth of control melanoma cells, but had little
effect on the HK2-OE melanoma cells (Figures 2C–2E). Taken
together, these results support the intriguing model that tumor
cells with increased rates of aerobic glycolysis are better able
to evade anti-tumor CD4+ T cell responses.
Glucose Deprivation Suppresses TCR-Dependent
Activation of Ca2+ and NFAT Signaling
To better understand how glucose deprivation alters TH1 cell
functions, we examined how glycolysis affects TCR signaling
after TCR stimulation using several approaches. First, we
observed that the induction of the immediate early gene Nur77
(as measured using a Nur77-eGFP reporter that reads out TCR
signaling in a Ca2+-dependent manner; Moran et al., 2011) was
suppressed in glucose-poor conditions or in the presence of
2-DG (Figure 3A). In contrast, the amount of phosphorylated
ERK1/2 (pERK1/2) or AKT (pAKTS473 and pAKTT308) was
minimally affected following activation of TH1 CD4 T cells in
glucose-deprived conditions (Figure S3). The defect in Nur77
induction prompted us to more closely monitor cytoplasmic
calcium flux using the ratiometric Ca2+-sensitive dyes (Fluo-4
and Fura-Red) and flow cytometry, and this revealed that
glucose deprivation profoundly repressed TCR-induced Ca2+
Figure 3. Glycolysis Modulates the Ca2+-NFAT1 Signaling Pathway in CD4+ T Cells
(A) Naive CD4+ T cells from Nur-77-eGFP mice were left unstimulated or stimulated with anti-CD3/anti-CD28 mAbs for 5 hr in the indicated conditions and GFP
fluorescence was measured by flow cytometry. Glc.: glucose; 2-DG: 2-deoxy-D-glucose.
(B and C) Intracellular Ca2+ levels were measured in Fluo-4- and Fura-Red-labeled TH1 CD4+ T cells cultured in 10 mM glucose or 0.1 mM glucose before and
after activation with anti-CD3 crosslinking antibodies (B) or ionomycin (C). The ratio of Fluo-4 and Fura-Red fluorescence was measured using flow cytometry.
(D) Intracellular Ca2+ levels were measured as above in naive CD4+ T cells isolated from wild-type (Wt) or GLUT-1-knockout (Glut1-KO) mice.
(E) TH1 CD4
+ T cells were stimulated with anti-CD3/anti-CD28 in the indicated conditions and amounts of phospho-PLCg1 were measured by flow cytometry.
(F) TH1 cells were stimulated with ionomycin in medium containing 10mM or 0.1 mM glucose for 10min and the cytoplasmic versus nuclear distribution of NFAT1
and NFAT2 was determined by Amnis Imagestream. Representative histograms and images show the similarity profiles of NFAT1 (yellow, left) or NFAT2 (red,
right) with DAPI staining to measure nuclear localization. The percentage of T cells with nuclear NFAT1 or NFAT2 is shown.
(G) Heat map shows normalized expression of select genes associated with T cell anergy (Safford et al., 2005) in TH1 cells stimulated for 5 hr with anti-CD3/anti-
CD28 mAbs in glucose-sufficient (10 mM) or glucose-deficient (0.1 mM) conditions.
Data shown are representative of two (D and E) and three (A–C, F) independent experiments or cumulative of three (G) independent experiments (n = 2 mice/
group).flux in activated TH1 cells (Figure 3B). Moreover, reducing aero-
bic glycolysis in activated TH1 cells by glucose deprivation or
deletion of the glucose transporter 1 (Macintyre et al., 2014)
also suppressed ionomycin-induced cytoplasmic Ca2+ accumu-
lation (Figures 3C and 3D). This latter result indicated that the
defect in Ca2+ flux could be IP3-independent because ionomycin
triggers Ca2+ efflux from the ER in an IP3-independent manner.CIn agreement, glucose deprivation did not affect TCR-induced
phosphorylation of PLCg-1 in TH1 cells (Figure 3E). Altogether,
these results suggested that glucose-deprivation dampened
the magnitude of TCR-induced Ca2+ flux, and consequently
CD4+ T cell effector functions.
Interestingly, anergic T cells, which have similar functional
defects to those observed with glucose-deprivation, alsoell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc. 1221
Figure 4. Glycolysis Sustains Cytoplasmic
Ca2+ Accumulation via Modulation of
SERCA-Mediated Calcium Reuptake
(A) Intracellular calcium levels were measured in
Fluo-4- and Fura-Red-labeled CD4+ T cells
cultured in Ca2+-free (left) or Ca2+-containing me-
dia (right) in 10mMglucose or 2-DGwith or without
thapsigargin (Tg).
(B) IntracellularCa2+ levelsweremeasuredasabove
in naive CD4+ T cells isolated fromwild-type (Wt) or
GLUT-1-knockout (Glut1-KO) mice and cultured in
Ca2+-containing media with or without Tg.
(C) Naive CD4+ T cells were left unstimulated or
stimulated with ionomycin in the presence of
10 mM glucose, 2-DG or 2-DG plus Tg for 10 min
and the cytoplasmic versus nuclear distribution of
NFAT1 was determined by Amnis Imagestream.
Representative histograms (left) and images (right)
show the similarity profiles of NFAT1/DAPI staining
to measure NFAT1 nuclear localization. The fre-
quency of T cells with nuclear NFAT1 is shown.
(D) Control or 2-DG treated TH1 cells were stimu-
lated with anti-CD3/anti-CD28 mAbs for 5 hr in the
absence or presence of Tg. The expression of
CD40L and IFNg was analyzed by flow cytometry.
(E) Western blots showing the amount of SERCA
protein in Jurkat T cells treated with or without
2-DG for 30 min.
(F) Ca2+-uptake using radiolabeled 45CaCl2 was measured in ER microsomal fractions isolated from Jurkat T cells treated with or without 2-DG for 10 or 30 min.
Data shown are representative of two (E and F) and three (A and B, C–E) independent experiments (n = 3/group in D and F. Data are expressed as mean ± SD and
*p < 0.05 by unpaired Student’s t test.display defects in Ca2+ signaling (Schwartz, 2003). Other work
has shown that the reduced Ca2+ signaling in anergic CD8
T cells impairs the nuclear localization of NFAT1, but not that
of NFAT2, indicating differential sensitivity to cytoplasmic
Ca2+ levels between these two transcription factors (Srinivasan
and Frauwirth, 2007). These phenotypes prompted us to
examine the cellular distribution of NFAT1 and 2 and expres-
sion of anergy-associated genes in glucose-deprived TH1 cells
(Safford et al., 2005). In agreement with the prior study (Sriniva-
san and Frauwirth, 2007), nuclear translocation of NFAT1,
but not NFAT2, was severely compromised in glucose-
deprived TH1 cells (Figure 3F). Importantly, 5 hr of glucose
deprivation led to increased expression of several ‘‘anergy’’
signature genes, including Egr2, Egr3, Irf4, Hspa1a, Gadd45b,
and Nfatc1 as previously described (Figure 3G, note the
augmented expression of some of these genes in TILs in Fig-
ure 1D) (Safford et al., 2005). Collectively, these results identi-
fied that glycolysis is critical for sustaining high amounts of
Ca2+-NFAT signaling in TH1 cells and that glucose-deprivation
results in CD4 T cell dysfunction and expression of anergy-
associated genes.
Glycolysis Modulates SERCA-Mediated ER Calcium
Uptake Activity
Stimulation of the TCR initially triggers Ca2+ efflux from the ER,
which subsequently induces extracellular Ca2+ import via the
calcium-release-activated calcium (CRAC) channel (Feske
et al., 2012). To distinguish ER Ca2+ efflux from extracellular
Ca2+ influx, we stimulated CD4+ T cells in the presence or
absence of 2-DGwith ionomycin in Ca2+-free or Ca2+-containing1222 Cell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc.media and found that 2-DG treatment diminished ionomycin-
induced cytosolic accumulation in either condition (Figure 4A,
compare red and blue lines in left and right). This suggested
that glycolysis is important for maintenance of cytosolic Ca2+
levels to support T cell activation. Several Ca2+ channels
expressed on the plasma membrane (plasma membrane Ca2+
ATPase: PMCA), mitochondrial membrane (mitochondrial Ca2+
uniporter: MCU), and ER membrane (SERCA) could lower
cytosolic Ca2+ levels, so we next tested if blocking these Ca2+
channels could restore Ca2+ flux in glucose-deprived T cells. In
contrast to blocking PMCA and MCU channels, treatment with
the SERCA inhibitor thapsigargin (Tg) increased Ca2+ flux in
2-DG treated or Glut1-KOCD4+ T cells (compare blue and green
lines, Figures 4A and 4B and Figure S4). This result suggested
that glucose-deprived T cells have increased SERCA activity
that suppressed maximal Ca2+ flux. Importantly, Tg treatment
also restored nuclear translocation of NFAT1 (Figure 4C) as
well as IFNg and CD40L production (Figure 4D) in 2-DG
treated TH1 cells. Western blotting of Jurkat T cells showed
that 2-DG treatment did not affect the overall amounts of SERCA
compared to control cells (Figure 4E), suggesting that the
increase in ER Ca2+ re-uptake stemmed from increased SERCA
activity. Indeed, measurement of radio-labeled Ca2+ uptake in
ER vesicles isolated from Jurkat T cells revealed that 2-DG treat-
ment increased SERCA-dependent Ca2+ uptake by 2-fold
compared to the control cells (Figure 4F). Taken together, these
findings strongly indicate that glycolysis suppresses SERCA ac-
tivity and consequently, glucose deprivation leads to defective
Ca2+-NFAT signaling and effector functions in glucose-deprived
T cells.
Figure 5. PEP Suppresses SERCA-Mediated ER Calcium Reuptake
(A) Illustration of the glycolysis pathway and the targets of the indicated glycolytic inhibitors. 2-DG: 2-deoxyglucose; IAA: iodoacetate; OXA: oxalate.
(B) Heatmap shows the normalized concentrations of the indicated glycolytic metabolites in CD4+ T cells stimulated with anti-CD3/anti-CD28mAbs for 1 hr in the
absence or presence of the glycolytic inhibitors described in (A) as measured by LC-QE-MS.
(C) Intracellular Ca2+ levels were measured in Fluo-4- and Fura-Red-labeled TH1 cells treated with indicated glycolytic inhibitors before and after activation with
ionomycin.
(D–F) TH1 cells were left alone or stimulated with anti-CD3/anti-CD28 mAbs for 5 hr in 10 mM glucose in the absence or presence of indicated glycolytic inhibitors
and the expression of CD40L (D), IFNg (E) and TGFb (F) was measured by flow cytometry (D) or ELISA (E and F).
(G andH) CD4+ T cells were transducedwith empty vector control retroviruses (RV, Ctrl-KD) or those expressing enolase-1 shRNAi (eno1-KD). RV-infected T cells
were left alone or stimulated with ionomycin for 10 min and the cytoplasmic versus nuclear distribution of NFAT1 was determined by Amnis Imagestream as
described in Figure 3F (G), or alternatively were stimulated with anti-CD3/anti-CD28mAbs in vitro in the presence of 10mM glucose for 5 hr and the expression of
IFNg, IL-2 and CD40L was analyzed by flow cytometry (H).
(I) Intracellular Ca2+ levels in CD4+ T cells that were partially permeabilized and recovered in the absence or presence of PEP were measured as in (C) in the
absence or presence of glycolytic inhibitor IAA.
(J) Ca2+-uptake assay as described in Figure 4F was performed on ER microsomal fractions isolated from Jurkat T cells cultured in the presence or absence of
glucose or exogenous PEP. The addition of Tg served as a specificity control for SERCA-dependent activity.
Data shown are representative of two (H and J) and three (C and D,G and I) independent experiments or cumulative of three (B, E and F) independent experiments.
Data are expressed as mean ± SD and *p < 0.05 by unpaired Student’s t test.The Glycoloytic Metabolite Phosphoenolpyruvate
Regulates Ca2+-NFAT Signaling in TH1 CD4+ T Cells by
Inhibiting SERCA Activity
To determine which steps of glycolysis regulate cytoplasmic
Ca2+ accumulation and T cell effector functions, TH1 cells
were treated with 2-DG, iodoacetate (IAA) and oxalate (OXA),
to inhibit hexokinase (HK), glyceraldehyde phosphate dehydro-
genase (GAPDH), and pyruvate kinase (PK), respectively, at
doses that showed comparable inhibition of lactate production
(Figure 5A and data not shown). The glycolytic metabolitesCwere examined by high-resolution liquid-chromatography Q-ex-
active mass spectrometry (LC-QE-MS) in the CD4+ T cells
stimulated in the absence or presence of the inhibitors and as ex-
pected, the levels of 3- and 2-phosphoglycerate (3-PG/2-PG),
and phosphoenolpyruvate (PEP) were suppressed by 2-DG
and IAA, but promoted by OXA (Figures 5B and S5A). Interest-
ingly, 2-DG and IAA, but not OXA, suppressed TH1 cell Ca2+
flux after ionomycin stimulation (Figure 5C) and CD40L and
IFNg production after TCR stimulation (Figures 5D and 5E). Like-
wise 2-DG and IAA, but not OXA, augmented TGFb productionell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc. 1223
(Figure 5F). These results suggested that a metabolite produced
downstream of GAPDH and upstream of PK fine-tunes Ca2+
signaling and TH1 effector functions.
We hypothesized that such a metabolite may be PEP because
of the above inhibitor studies and because TCR activation in-
creases expression of the less-active M2 isoform of pyruvate ki-
nase (PKM2) (Wang et al., 2011a), which allows the accumulation
of several metabolic intermediates, including PEP, in proliferating
cells (Vander Heiden et al., 2010). To more rigorously confirm the
role of PEP in regulating the Ca2+-NFAT pathway, we knocked
down enolase 1 (Eno-1), the glycolytic enzyme that converts
2-PG into PEP (Figure S5B), and analyzedNFAT1 nuclear translo-
cation and expression of IFNg and CD40L in activated CD4+
Tcells. Thisshowed thatNFAT1nuclear translocationand thepro-
duction of IFNg and CD40L (Figures 5G and 5H)were impaired by
Eno-1 knock down. Additionally, treating TH1 CD4+ T cells with
PKM2activatorDASS,whichwill decrease intracellularPEP levels
(data not shown) (Anastasiou et al., 2012), similarly suppressed
the production of IFNg and CD40L (Figure S5C). Finally, supple-
mentation of PEP (1 mg/ml), but not fosfomycin (a structurally
related analog), to glucose-deprived CD4+ T cells restored Ca2+
flux in thepresenceof IAA (Figures5I andS5D).Together theseex-
periments narrowing in on the enzymes regulating PEP meta-
bolism in cells, demonstrate that the accumulation of PEP is crit-
ical for sustaining Ca2+-NFAT signaling.
To directly test if PEP can inhibit SERCA-mediated calcium
uptake, we repeated the ER Ca2+ uptake assay by isolating ER
vesicles from Jurkat T cells cultured in the presence or absence
of glucose. This showed that glucose deprivation promoted ER
Ca2+ uptake ability; however, PEP supplementation to the ER
vesicle fraction significantly suppressed ER Ca2+ uptake indi-
cating that PEP can inhibit SERCA activity (Figure 5J). Given
that oxidation of SERCA on cysteine residues (e.g., Cys674
and Cys675) reduces SERCA activity (Sharov et al., 2006), we
then examined whether glucose deprivation in T cells affects
the redox state of SERCA using fluorescent thiol probes that
measure the abundance of reduced cysteine residues on
proteins. Jurkat T cells were cultured in glucose-replete
or -deplete conditions, and ER vesicles were isolated and
labeled with fluorescent probes that covalently bind to free
thiols. SERCA was then immunoprecipitated from the ER vesi-
cles and the amount of sample fluorescencemeasured indicated
the abundance of reduced cysteines in SERCA. ER vesicles from
glucose-deprived cells treated with H2O2 or b-mercaptoethanol
(b-ME) served as positive controls for maximal cysteine oxida-
tion and reduction, respectively. These experiments showed
that compared to cells cultured in glucose-replete medium,
glucose-deprivation increased the abundance of free thiols on
SERCA, indicative of a more reduced state (Figure S5E). The
addition of PEP, but not fosphomycin, to the ER vesicles
decreased thiol abundance on SERCA similar to the amounts
observed with H2O2 (Figure S5E). This result suggests that
PEP likely impairs SERCA activity by promoting cysteine oxida-
tion. To further explore this possibility, we found that treating
glucose-deprived CD4+ T cells with H2O2, which suppresses
SERCA activity via cysteine oxidation (Qin et al., 2013), could
restore their ability to flux Ca2+ (Figure S5F). Collectively, these
results identify a previously uncharacterized role for the metab-1224 Cell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc.olite PEP in controlling Ca2+ signaling through inhibition, and
likely the oxidation, of SERCA in T cells. These findings elucidate
a nutrient-sensing mechanism by which T cells integrate their
functional states with their metabolic states.
Metabolic Reprogramming of TILs Boosts Tumoricidal
Activities in the Glucose-Deprived Tumor
Microenvironment
The above findings support a model whereby the hyper-anabolic
metabolic states of tumor cells reduce the availability of nutrients,
such as glucose, and prevent TILs from sustaining Ca2+-NFAT
signaling and effector functions, in part, from PEP insufficiency.
If so, it may be possible to metabolically reprogram anti-tumor
T cells to increase their fitness and function in the tumormicroen-
vironment. Because the data indicated that PEP was a critical
metabolite controlling T cells function, we speculated that over-
expression of phosphoenolpyruvate carboxykinase 1 (PCK1),
whichconverts oxaloacetate (OAA) intoPEP, couldbolster the tu-
moricidal activity of TILs (Figure 6A). To examine this hypothesis,
PCK1 (PCK1-OE) was overexpressed in Trp-1 CD4+ T cells spe-
cific for the melanoma antigen gp75/tyrosinase-related protein 1
(TRP-1), and this demonstrated that PCK1-OE specifically
boosted PEP levels in T cells cultured in glucose-poor conditions
(Figure 6B, compare blue and green bars), but had little effect on
the amount of PEP above and beyond that normally found in
T cells cultured in glucose-rich conditions. In contrast to control
cells, PCK1-overexpression also reversed the effects of
glucose-deprivation on Ca2+ flux and NFAT1 nuclear localization
inCD4+T cells (Figures 6Cand 6D). It is important to note that the
effects of glucose deprivation and PCK1-OE on CD8 T cell Ca2+
flux and effector functions were very similar to those observed
in CD4 T cells. For example, blocking PEP accumulation via
glycolytic inhibitors or PKM2 activators also diminished CD8+
T cell IFNg production (Figures S6A and S6B). Additionally,
PCK1-overexpression restored Ca2+ flux in glucose-deprived
CD8+ T cells (Figure S6C). Thus, PCK1-OE lessened the depen-
dence of both CD4 and CD8 T cells on glucose for Ca2+-NFAT1
signaling in glucose-poor conditions.
Next, we examinedwhether PCK1-OE could enhance the anti-
tumor responses of tumor-infiltrating Trp-1 CD4+ T cells. To this
end, PCK1-OE or control Trp-1 CD4+ T cells were adoptively
transferred into mice that contained engrafted B16 melanomas.
Strikingly, PCK-OE increased Trp-1 CD4+ T cell production of
IFNg and CD40L over that of control cells in the tumors, but
not in the spleen or draining lymph nodes where glucose is
more abundant (Figure 6E). Additionally, relatively higher
amounts of costimulatory ligand (CD86) and MHC class I and II
expression were observed on TAMs in mice that received
PCK1-OE Trp-1 CD4+ T cells compared to those that received
control cells (Figure 6F), suggesting that restored effector func-
tions by PCK1-OE Trp-1 CD4+ T cells promoted the maturation
of TAMs. Most importantly, transfer of PCK1-OE Trp-1 CD4+
T cells suppressed melanoma growth (Figure 6G) and prolonged
the survival of B16 melanoma-bearing mice (Figure 6H)
compared to the control T cells. Of note, a similar suppression
in tumor growth was observed in separate experiments when
PCK1 was overexpressed in Pmel CD8+ T cells, specific for
the melanoma antigen gp100 (Figures S6D and S6E). Taken
Figure 6. Overexpression of Phosphoenolpyruvate Carboxykinase 1 Boosts Ca2+-NFAT Signaling and Tumoricidal Activities of Tumor-
Specific CD4+ T Cells
(A) Illustration of the metabolic function of PCK1 in converting OAA to PEP.
(B–D) CD4+ T cells were transduced with control (Ctrl) or PCK-1 overexpressing (PCK1-OE) RVs. (B) Intracellular PEP levels were measured after culturing the
RV-transduced cells for 1 hr in the indicated conditions using a fluorescence-based assay. (C) Intracellular Ca2+ levels were measured in the transduced CD4+
T cells cultured in 10 mM or 0.1 mM glucose before and after activation with ionomycin.
(D) The cytoplasmic versus nuclear distribution of NFAT1 was determined in the RV-transduced CD4+ T cells stimulated with ionomycin in 10 mM glucose or
0.1 mM glucose for 10 min by Amnis Imagestream as described in Figure 5G.
(E–H) Melanoma-specific Trp-1+ CD4+ T cells transduced with Ctrl or PCK-1-OE RVs were adoptively transferred into B16 melanoma-bearing mice. (E and F)
Three days later, the donor Trp-1+ CD4+ T cells (E) or TAMs (F) were isolated from the indicated tissues and analyzed for expression of the indicated proteins by
flow cytometry. Rates of tumor growth (G) and animal survival (H) were determined over time.
Data shown are representative of two (D) and three (C) independent experiments or cumulative of two (F) (n = 2–3 mice/group/experiment), three (B, E) (n = 2–3
mice/group/experiment), and four (G and H) independent experiments (n = 3–4 mice/group/experiment). Data are expressed as mean ± SD (B and F) or mean ±
SEM (E) and *p < 0.05 by unpaired Student’s t test.together, our results provide strong evidence that metabolic
reprogramming of both CD4 and CD8 T cells is a promising
strategy to boost effector functions of tumor-specific T cells in
nutrient stressed conditions.
DISCUSSION
It is well appreciated that deregulated metabolism drives tu-
mor cell growth, but it is underappreciated how this affectsCthe metabolic or functional states of cells that infiltrate tumors
(Pearce et al., 2013). Do cancer cells play a ‘‘metabolic tug-of-
war’’ with immune cells in tumors? Our work suggests they
may because tumors with elevated rates of glycolytic activity
were better able to elude T cell immunosurveillance. Further,
TILs displayed signs of glucose deprivation, including impaired
production of IFNg and CD40L, but increased expression of
TGFb and genes associated with T cell anergy. This led to
the discovery that glycolysis controls T cell Ca2+-NFATell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc. 1225
signaling and effector functions via the glycolytic metabo-
lite PEP. Importantly, manipulation of this pathway by meta-
bolically reprogramming TILs to increase PEP production
yielded stronger anti-tumor responses. This work reveals
that a glucose-poor tumor microenvironment can impose
immunosuppressive properties on TILs and provides critical
proof-of-concept evidence that metabolic reprogramming
of tumor-specific T cells can be an adjunct form of
immunotherapy.
In addition to other well-known immunosuppressive factors,
our work indicates that glucose deprivation is another critical
environmental restriction in solid tumors that restrains the
tumoricidal functions of infiltrating tumor-specific CD4+
T cells. Support for this model also stems from studies showing
that tumor-specific T cells regain effector function after being
cultured in vitro for a short period of time (6–24 hr) in nutrient
replete conditions (Wang et al., 2011b). Targeted inhibition of
oncogenes, such as BrafV600E and KrasG12D, can stimulate
T cell infiltration and production of IFNg in tumors, and it is
possible that these effects stem from their suppression of tumor
cell aerobic glycolysis (Ho et al., 2014; Ying et al., 2012). How-
ever, further in vivo analyses are required to determine if tumor
cells restrict glucose to infiltrating T cells through their own
glycolytic activities and if this contributes to an immunosup-
pressive tumor microenvironment. Given that PD-1 signaling
suppresses Akt-mTOR pathway and aerobic glycolysis (Parry
et al., 2005; Staron et al., 2014), the therapeutic effects of
anti-PD-1 immunotherapy will most certainly rely on TILs re-
engaging aerobic glycolysis to regain proliferation and function.
Indeed, rapamycin treatment abrogated the therapeutic effects
of anti-PDL1 blockade on exhausted CD8 T cells during chronic
viral infection (Staron et al., 2014). That both tumor cells and
activated T cells share similar requirements for anabolic meta-
bolism raises important considerations for designing drug
treatments that combine metabolically targeted therapies with
immunotherapy. For example, drugs that suppress tumor cell
glycolysis may have poor efficacy long-term because of their
unintended effects on TIL function. Therefore, as new treat-
ments are tested, the effects of anti-cancer drugs on the meta-
bolism and function of tumor infiltrating immune cells should be
considered and examined.
It is clear that certain metabolic pathways serve as ‘‘meta-
bolic checkpoints’’ to control T cell activation and function,
but mechanistically how this occurs is not well understood.
Our study uncovers a mechanism through which the glycolytic
intermediate PEP regulates the amplitude of Ca2+ flux and
NFAT activation to fine-tune T cell effector function. Although
PEP could inhibit SERCA activity and increase its oxidative
state, the precise molecular mechanism(s) by which this occurs
remains unknown. Possibly PEP directly conjugates to or oxi-
dizes cysteine residues on SERCA or alternatively PEP could
serve as a high-energy phosphate donor to phosphorylate
SERCA or other proteins that inhibit its activity (Vander Heiden
et al., 2010). Future biochemical studies are needed to pre-
cisely characterize which residues in SERCA, if any, are modi-
fied by PEP.
Metabolic flexibility allows activated T cells to adapt to
changes in glucose availability by utilizing alternative substrates1226 Cell 162, 1217–1228, September 10, 2015 ª2015 Elsevier Inc.for energy production (Blagih et al., 2015; Frauwirth et al., 2002).
Possibly, TILs become dependent on other carbon sources,
such as lactic acid and free fatty acids (FFAs) abundant in the
tumor microenvironment, and this not only changes the meta-
bolic activities of TILs, but also their effector functions. Indeed,
it is interesting to consider which carbon sources are used by
the PCK-1 overexpressing T cells to manufacture PEP when
glucose-deprived; our preliminary studies in vitro suggest that
both lactic acid and FFAs may be involved (data not shown).
Future in-depth metabolite profiling of TILs will help to charac-
terize the nutrients they consume and the metabolic pathways
they exercise in vivo, through which, one may develop more
robust methods to harness anti-tumor T cell responses via meta-
bolic manipulation.
Overall, our findings describe ametabolic checkpoint for T cell
activity in tumors in which a glycolytic metabolite, PEP, serves as
an intracellular sensor for glucose availability in the environment
to regulate T cell activation and production of effector molecules.
Together with another recent discovery identifying a secondary
role for GAPDH in inhibiting IFNg mRNA translation in T cells
(Chang et al., 2013), these finding demonstrate that both metab-
olites and metabolic enzymes have adopted additional roles as
metabolic checkpoint regulators to control specialized functions
in T cells. From a therapeutic standpoint, better delineation of the
metabolic pathways or enzymes differentially utilized by cancer
cells and cancer-specific T cells could reveal vulnerable drug-
targets in cancer cells. Additionally, rewiring the metabolic activ-
ity of TILs, as demonstrated herein and elsewhere (Doedens
et al., 2013), could pose a new strategy for enhancing the po-
tency and durability of ACT.
EXPERIMENTAL PROCEDURES
Mice, Tumor Engraftment, and Tumor Induction
The inducible mouse model of melanoma was previously described (Dankort
et al., 2009) and Trp-1 TCR transgenic mice were purchased from Jackson
Laboratory (Bar Harbor, ME). For melanoma cell engraftment, 2x105 B16 or
Braf/Pten melanoma cells were suspended in 50 ml of PBS and then injected
subcutaneously into wild-type C57BL/6 mice (Jackson Laboratory). All mouse
experiments were performed according to the approved procedures of the
Yale Institutional Animal Care and Use Committee.
ER Vesicle Isolation and Calcium Uptake Assay
Jurkat cells were cultured in glucose-free RPMI with 10% dialyzed FBS in the
indicated conditions for 30min. ERmicrosomal fractions were then isolated as
previously described (Ho et al., 2011). ER vesicles were then analyzed by a
calcium uptake assay with 45CaCl2 as the tracer of calcium uptake, as previ-
ously described (Borge andWolf, 2003). For analysis of the effect of PEP on ER
calcium uptake, the calcium uptake assay was performed in the presence of
6 mM PEP.
Fluorescence Labeling of SERCA Thiol Groups
ER microsomal fractions were then isolated from Jurkat cells cultured in
glucose-free RPMI with 10% dialyzed FBS in 10 mM glucose or 0.1 mM
glucose for 30 min. Two hundred micrograms of ER microsomal fraction
was re-suspended in 20 mM sodium phosphate (pH7.4) buffer and then incu-
bated with control vehicle, 1 mg/ml PEP, 1 mg/ml fosphomycin, 5 mM H2O2 or
1 mM b-mercaptoethanol for 10 min at 37C. 200 mM Thiol-fluorescent probe
IV (EMDMillipore, Billerica, MA) in the presence of 1% SDS for 30 min at 37C.
Then the reaction mixture was subjected for immunoprecipitation of SERCA or
control IgG. The fluorescence intensity of the immunoprecipiates was then
determined.
Statistical Analysis
Results were presented as mean ± SD or mean ± SEM and statistical signifi-
cance was examined by an unpaired Student’s t test. p value < 0.05 was
considered as statistically significant.
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